Targeting INF2 with DiosMetin 7-O-β-D-Glucuronide: a new stratagem for colorectal cancer therapy.

Journal: BMC cancer
Published Date:

Abstract

BACKGROUND AND PURPOSE: Colorectal cancer (CRC) is the third most prevalent malignancy in the gastrointestinal tract and the second leading cause of cancer-related deaths. Despite the identification of numerous biomarkers, their non-specific distribution across different cell types complicates the development of targeted therapies. Therefore, this study aims to identify specific biomarkers for CRC and utilize them for the development of targeted therapies.

Authors

  • Zhirui Zeng
    Department of Colorectal Surgery, Affiliated Hospital of Guizhou Medical University, Guiyang, 550004, China.
  • Yun Ke
    Department of Colorectal Surgery, Affiliated Hospital of Guizhou Medical University, Guiyang, 550004, China.
  • Fei Huang
    Alibaba Damo Academy, 969 West Wen Yi Road, Yu Hang District, Hangzhou, Zhejiang, China.
  • Hangyi Li
    Department of Colorectal Surgery, Affiliated Hospital of Guizhou Medical University, Guiyang, 550004, China.
  • Xiaomin Zhang
    Department of Occupational and Environmental Health, State Key Laboratory of Environmental Health (Incubating), School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Dahuan Li
    Engineering Research Center of Chronic Disease Diagnosis and Treatment, School of Basic Medicine, Guizhou Medical University, Guiyang, 550025, China.
  • Yingmin Wu
    Engineering Research Center of Chronic Disease Diagnosis and Treatment, School of Basic Medicine, Guizhou Medical University, Guiyang, 550025, China.
  • Tengxiang Chen
    Engineering Research Center of Chronic Disease Diagnosis and Treatment, School of Basic Medicine, Guizhou Medical University, Guiyang, 550025, China. txch@gmc.edu.cn.
  • Yunhuan Zhen
    Department of Colorectal Surgery, Affiliated Hospital of Guizhou Medical University, Guiyang, 550004, China. yunhuanzhen72@163.com.